Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Guaifenesin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guaifenesin SCHEMBL160234 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL31161209 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL4322 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL4321 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL29759010 | 0.98 | CYP1A2 (1.00) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL2459821 | 0.96 | CYP1A2 (0.96) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL28898302 | 0.90 | CYP1A2 (0.84) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| Guaifenesin SCHEMBL28062894 | 0.90 | CYP1A2 (0.84) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| SCHEMBL29941729 | 0.89 | LMNA (0.82) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 | |
| SCHEMBL2328960 | 0.89 | LMNA (0.82) | CYP1A2LMNAAGTR1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080292699-A1 | SOLID PHARMACEUTICAL DOSAGE UNIT FOR ALLEVIATING SYMPTOMS OF RHINORRHEA | SOVEREIGN PHARMACEUTICALS, LTD. (US) | 2008-11-27 | — | — | US | disclosed |